Fig. 1

METTL3 expression and CD33⁺ MDSC distribution in patients with CC. a, b The immunohistochemical staining for METL3 and CD33 CC specimens (× 400). c The isotype antibody IgG was included (× 400). d Immunofluorescence staining for METTL3 (red) and CD33⁺ (green) in CC specimens; the white arrows point to the METTL3⁺ and CD33⁺ cells. The images were taken by fluorescence microscope. HLA-DR⁻CD33⁺CD11b⁺ cells were gated by a FACS gating strategy and were defined as MDSCs in this study. e, f Representative density plots showed the MDSC population in the peripheral blood of healthy donors (HD) or CC patients, as well as in the immune cells from tumour tissues (TIL) or tumour-adjacent tissues (NIL). A statistical graph is included for the comparison between the indicated groups. (G-H) Representative immunoblotting shows the expression of METTL3 in the peripheral blood, TILs and NILs. A statistical graph is included for the comparison between the indicated groups. The experiments in e, f were performed at least three times, and the data were plotted as the mean ± SEM. Statistics were conducted with an unpaired Student’s t test, *P < 0.05, and ***P < 0.001 vs. the corresponding control